sharesgurusharesguru
  • Stocks
  • Ai Screener
  • Sectors
  • Watchlist
LoginSign Up
sharesguru
  • Home
  • Stocks
  • Ai Screener
  • Sectors
  • Watchlist
  • Profile
  • Contact Us
LoginSign Up
sharesguru

Discover the joy of investing.

All the financial data and tools you need, at one place.

Navigation

  • Home
  • Stocks
  • Sectors

Tools

  • Ai Screener
  • Watchlists

Company

  • Contact

Legal

  • Privacy Policy
  • Terms of Service
Copyright © 2025 Knowtilus Technologies Pvt. Ltd.
SummaryLatest NewsSector ComparisonEarnings ReportRevenue & GrowthPeersIncome StatementBalance SheetCash Flow
CAMLINFINE logo

CAMLINFINE - Camlin Fine Sciences Ltd Share Price

Chemicals & Petrochemicals
Sharesguru Stock Score

CAMLINFINE

44/100

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 4 years

₹103.69-0.98(-0.94%)
Market Closed as of Apr 13, 2026, 15:30 IST
Pros

Balance Sheet: Reasonably good balance sheet.

Cons

Past Returns: Underperforming stock! In past three years, the stock has provided -12% return compared to 10.2% by NIFTY 50.

Dilution: Company has a tendency to dilute it's stock investors.

Momentum: Stock has a weak negative price momentum.

Smart Money: Smart money is losing interest in the stock.

Technicals: SharesGuru indicator is Bearish.

Price to Sales Ratio

Revenue (Last 12 mths)

Net Income (Last 12 mths)

Sharesguru Stock Score

CAMLINFINE

44/100

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 4 years

Valuation

Market Cap1.99 kCr
Price/Earnings (Trailing)-32
Price/Sales (Trailing)1.1
EV/EBITDA18.66
Price/Free Cashflow-231.97
MarketCap/EBT-556.34
Enterprise Value2.55 kCr

Fundamentals

Revenue (TTM)1.8 kCr
Rev. Growth (Yr)5.8%
Earnings (TTM)-62.62 Cr
Earnings Growth (Yr)-396.6%

Profitability

Operating Margin1%
EBT Margin0.00%
Return on Equity-7.28%
Return on Assets-3.07%
Free Cashflow Yield-0.43%

Growth & Returns

Price Change 1W1%
Price Change 1M-23.7%
Price Change 6M-47%
Price Change 1Y-35.2%
3Y Cumulative Return-12%
5Y Cumulative Return-5.8%
7Y Cumulative Return11.7%
10Y Cumulative Return0.40%

Cash Flow & Liquidity

Cash Flow from Investing (TTM)-75.35 Cr
Cash Flow from Operations (TTM)26.72 Cr
Cash Flow from Financing (TTM)72.44 Cr
Cash & Equivalents87.44 Cr
Free Cash Flow (TTM)-15.72 Cr
Free Cash Flow/Share (TTM)-0.84

Balance Sheet

Total Assets2.04 kCr
Total Liabilities1.18 kCr
Shareholder Equity860.12 Cr
Current Assets1.17 kCr
Current Liabilities856.38 Cr
Net PPE630.01 Cr
Inventory530.95 Cr
Goodwill47.47 Cr

Capital Structure & Leverage

Debt Ratio0.32
Debt/Equity0.75
Interest Coverage-1.05
Interest/Cashflow Ops1.29

Dividend & Shareholder Returns

Dividend Yield0.15%
Shares Dilution (1Y)14.7%
Shares Dilution (3Y)22.3%
Pros

Balance Sheet: Reasonably good balance sheet.

Cons

Past Returns: Underperforming stock! In past three years, the stock has provided -12% return compared to 10.2% by NIFTY 50.

Dilution: Company has a tendency to dilute it's stock investors.

Momentum: Stock has a weak negative price momentum.

Smart Money: Smart money is losing interest in the stock.

Technicals: SharesGuru indicator is Bearish.

The Good, Bad and Ugly
Growth
Measures how quickly a company is expanding through metrics like revenue growth, earnings growth, and cash flow growth over time. Strong growth can indicate future potential.
Profitability
Shows how efficiently a company turns business activities into profit, using metrics like profit margins, return on equity (ROE), and return on assets (ROA).
Size
Indicates the company's market presence through metrics like market capitalization, total assets, and revenue. Size can influence stability and market influence.
Dilution Rank
Tracks how much the company's shares have increased or decreased over time. Lower dilution means existing shareholders maintain stronger ownership stakes.
Balance Sheet
Evaluates the company's financial health by analyzing assets, debts, and equity. A strong balance sheet indicates financial stability and flexibility.
Momentum
Measures the strength and speed of price movements, showing whether the stock is gaining or losing market favor over different time periods.
Technicals
Analyzes price patterns, trading volumes, and other market indicators to identify potential trading opportunities and market trends.
Smart Money
Tracks the investment activities of institutional investors, hedge funds, and other large financial players who often have deep research capabilities.
Insider Trading
Monitors buying and selling of company shares by executives, directors, and other insiders who may have unique insights into the company's prospects.

Investor Care

Dividend Yield0.15%
Shares Dilution (1Y)14.7%
Earnings/Share (TTM)-3.24

Financial Health

Current Ratio1.36
Debt/Equity0.75

Technical Indicators

RSI (14d)28.02
RSI (5d)53.78
RSI (21d)32.42
MACD SignalBuy
Stochastic Oscillator SignalHold
SharesGuru SignalSell
RSI SignalBuy
RSI5 SignalHold
RSI21 SignalHold
SMA 5 SignalSell
SMA 10 SignalSell
SMA 20 SignalSell
SMA 50 SignalSell
SMA 100 SignalSell

Summary of Latest Earnings Report from Camlin Fine Sciences

Summary of Camlin Fine Sciences's latest earnings call, featuring management's outlook on business performance, financial results, and analyst Q&A sessions that highlight key strategic initiatives and market challenges.

Management provided an optimistic outlook regarding future performance, especially in the Vanillin segment. For fiscal year 2027 (FY'27), the company anticipates a total sales volume of 4,000 metric tons of Vanillin, a significant increase from the 1,740 metric tons sold in the first nine months of FY'26. They expect Vanillin realizations to improve to around $14-$14.5 per kg, which is reflective of a 25% tariff reduction.

In terms of financial performance, management projected that overall revenue for the company would reach approximately Rs.2,200 crores in FY'27 and further increase to Rs.2,400 crores in FY'28. They projected EBITDA margins to improve between 12% to 14%, driven by enhanced sales volumes and realizations in the Vanillin segment along with 20%-25% growth in the Blends business.

Key forward-looking points emphasized include:

  1. A 25% reduction in tariffs is expected to boost Vanillin realizations significantly, allowing for improved margins.
  2. The integration of acquisitions like Vinpai is expected to positively influence revenue growth, where the company anticipates up to 50% growth in the blended business segments next year.
  3. The immediate focus is on minimizing losses from a recent fire incident at the Brazil facility, where stock worth approximately Rs.28 crores was lost. While they are adequately insured, there may be temporary margin impacts due to local sourcing needed to fulfill orders.
  4. An anticipated clean-up from the liquidation processes in Europe could stabilize costs and halt ongoing cash burns.

Overall, management seems confident in maintaining growth trajectories while managing transitioning challenges.

1. Question from Hrushikesh Shah: "Sir, my first question is currently our Vanillin realization at $12, right? And you mentioned that they may increase by $2 to $3. So, according to me, let's say your realization in the US is $18. If your tariffs move down by 25%, then your realization should increase by $6. So, where is the disconnect in this?"
Answer: The price in the US is around $18-$19, which is correct. However, we had to pay 50% duty to realize $12. With the duty reduced to 25%, our realization will improve to about $14-$14.5. This adjustment accounts for local competition without the duty.

2. Question from Hrushikesh Shah: "What is the volume guidance for FY'27?"
Answer: For FY'27, we expect total Vanillin sales, including methyl and ethyl, to be around 4,000 metric tons.

3. Question from Hrushikesh Shah: "What was the revenue for Vinpai for the full year?"
Answer: Vinpai's consolidated revenue has been around Rs. 13 crores monthly, so the annual turnover is approximately Rs. 150 crores.

4. Question from Hrushikesh Shah: "What do you think is our steady-state margin?"
Answer: Our steady-state gross margin should improve to 46%-47% in FY'27 due to increased Vanillin realizations and growth in the blends business. The EBITDA margin is expected to range between 12%-14%.

5. Question from Satish Kumar: "What is the duty right now in the US?"
Answer: The current duty is 25%. Once the trade deal is finalized, we expect this to drop to 18%.

6. Question from Satish Kumar: "What was the quantity of Vanillin we did not sell this quarter?"
Answer: We opted to delay the sale of about 200 tons to benefit from the lower duty in the next quarter, aiming for a better realization.

7. Question from Surya Narayan Patra: "Will Vanillin pricing in the US affect Europe too post-tariff?"
Answer: No, there will be a disparity. The anti-dumping duties in Europe are much higher, meaning pricing dynamics will remain different between the US and Europe.

8. Question from Surya Narayan Patra: "What is the impact of the Brazilian fire incident?"
Answer: While the blending unit is temporarily closed, the incident will not significantly impact our top-line revenue. However, we may face margin pressure short-term due to local sourcing.

9. Question from Rehan: "What would be the margin profile at EBITDA level for Vinpai and the other acquisitions?"
Answer: Vinpai is currently near breakeven with minimal EBITDA contribution, while Vitafor is stable with margins around 4%-12%.

10. Question from Rohan Advant: "What is the revenue guidance for '27 and '28?"
Answer: We are targeting around Rs. 2,200 crores for FY'27, growing to approximately Rs. 2,400 crores in FY'28, assuming current product pricing remains steady.

Share Holdings

Understand Camlin Fine Sciences ownership landscape with insights into key distribution patterns, offering investors a clear view of stakeholder dynamics.

Holding Pattern

Share Holding Details

Shareholder NameHolding %
Ashish Subhash Dandekar10.3%
Infinity Direct Holdings10.18%
Anfima Nv8.83%
Infinity Holdings6.2%
Infinity Direct Capital4.82%
Icici Prudential Commodities Fund4.8%
Camart Finance Limited2.77%
Nirmal Vinod Momaya1.88%
Franklin India Opportunites Fund1.69%
Anagha Subhash Dandekar1.57%
Vibha Agencies Pvt Ltd1.36%
Ajay Upadhyaya1.3%
Infinity Portfolio Holdings1.17%
Jagdish N Master1%
Cafco Consultants Limited0.78%
Radha Pandit0.04%
Anand Y Pandit0.01%
MK Falcon Agro tech Pvt. Ltd.0%

Overall Distribution

Distribution across major stakeholders

Ownership Distribution

Distribution across major institutional holders

Is Camlin Fine Sciences Better than it's peers?

Detailed comparison of Camlin Fine Sciences against industry peers, highlighting key financial metrics, valuation ratios, and performance indicators to provide competitive context within the sector.

Ticker
Name
Mkt Cap
Revenue
Price %, 1M
Returns, 1Y
P/E
P/S
Rev 1-Yr
Inc 1-Yr
VINATIORGAVinati Organics12.53 kCr2.31 kCr-10.30%-21.70%28.295.43--
JUBLINGREAJubilant Ingrevia10.22 kCr4.3 kCr+15.00%+1.10%38.162.38--
SEQUENTSequent Scientific8.95 kCr2.15 kCr+4.00%+49.60%84.814.17--
GALAXYSURFGalaxy Surfactants6.39 kCr5.11 kCr+0.50%-17.60%22.771.25--
BALAMINESBalaji Amines3.51 kCr1.41 kCr+8.10%-10.20%24.462.48--

Sector Comparison: CAMLINFINE vs Chemicals & Petrochemicals

Comprehensive comparison against sector averages

Comparative Metrics

CAMLINFINE metrics compared to Chemicals

CategoryCAMLINFINEChemicals
PE-32.07 41.87
PS1.113.88
Growth7.7 %4.8 %
0% metrics above sector average
Key Insights
  • 1. CAMLINFINE is NOT among the Top 10 largest companies in Specialty Chemicals.
  • 2. The company holds a market share of 1.2% in Specialty Chemicals.
  • 3. In last one year, the company has had an above average growth that other Specialty Chemicals companies.

Income Statement for Camlin Fine Sciences

Consolidated figures (in Rs. Crores) /
Description(%) Q/QMar-2025Mar-2024Mar-2023Mar-2022Mar-2021Mar-2020
Revenue From Operations3.3%1,6671,6131,6821,4121,1871,049
Other Income-13.3%14165.8334.983.43
Total Income3.2%1,6811,6291,6871,4451,1921,053
Cost of Materials5.2%786747856728488500
Purchases of stock-in-trade3.5%11811461457853
Employee Expense7.3%192179163145120100
Finance costs67.8%1006058363843
Depreciation and Amortization-19.2%647963564433
Other expenses-6.7%417447500355301285
Total Expenses-3.3%1,6221,6781,5971,3511,087994
Profit Before exceptional items and Tax215%59-49.44909410558
Exceptional items before tax78.7%-9.82-49.8-9.68000
Total profit before tax147.9%49-99.24809410558
Current tax70.8%422529322725
Deferred tax-112.7%-42.06-19.24121.53123.48
Total tax-120.1%0.075.6341344028
Total profit (loss) for period-50.3%-158.12-104.8840606530
Other comp. income net of taxes-177.8%-12.231820-7.771141.3
Total Comprehensive Income-94.9%-170.35-86.91605317931
Earnings Per Share, Basic-37.2%-8.03-5.583.454.654.132.5
Earnings Per Share, Diluted-37.5%-7.94-5.53.414.563.682.5
Debt equity ratio-0.720-000
Debt service coverage ratio-0.010-000
Description(%) Q/QDec-2025Sep-2025Jun-2025Mar-2025Dec-2024Sep-2024
Revenue From Operations-0.7%457460424437433423
Other Income-46%2.944.598.569.591.3412
Total Income-0.9%460464432447435435
Cost of Materials28.4%268209226195173223
Purchases of stock-in-trade-58.1%1432172.364554
Employee Expense6.8%646060505252
Finance costs-5.6%181916163426
Depreciation and Amortization-11.1%171917181421
Other expenses3.4%123119108113116108
Total Expenses1.3%470464437413433427
Profit Before exceptional items and Tax-1419.2%-10.090.27-5.15341.528.23
Exceptional items before tax--17.5100-5.590-151.04
Total profit before tax-3817.8%-27.60.27-5.15291.52-142.81
Current tax-26%4.415.615.98144.3216
Deferred tax-667.1%-4.370.3-5.99-6.042.82-42.61
Total tax-119.3%0.055.91-0.017.957.14-26.2
Total profit (loss) for period-138.9%-37.1-14.95-10.680.11-7.47-116.11
Other comp. income net of taxes270.7%4.38-0.98125.79-12.110.03
Total Comprehensive Income-99.2%-32.72-15.931.255.9-19.58-116.08
Earnings Per Share, Basic-65.3%-1.91-0.76-0.53-0.04-0.243-5.98
Earnings Per Share, Diluted-65.3%-1.91-0.76-0.52-0.04-0.24-5.93
Debt equity ratio----0.72--
Debt service coverage ratio----0.01--
Standalone figures (in Rs. Crores) /
Description(%) Q/QMar-2025Mar-2024Mar-2023Mar-2022Mar-2021Mar-2020
Revenue From Operations14.6%886773789686600580
Other Income11.1%211929195.4724
Total Income14.5%907792818704606604
Cost of Materials26.6%539426403382384377
Purchases of stock-in-trade114.5%178.465.547.621613
Employee Expense9.2%726660533928
Finance costs22.6%665457333328
Depreciation and Amortization8.3%534933271911
Other expenses10.6%262237236161121103
Total Expenses10%935850752668590559
Profit Before exceptional items and Tax51.6%-27.43-57.767361644
Exceptional items before tax-3210.6%-96-1.9300-0.5-3.14
Total profit before tax-105.2%-123.43-59.6367361541
Current tax-1.660146.42.787.5
Deferred tax-438.7%-48.78-8.245.153.813.963.06
Total tax-420.8%-47.12-8.2419106.7411
Total profit (loss) for period-47.6%-76.31-51.3948268.2831
Other comp. income net of taxes-48.1%-0.54-0.04-0.66-0.15-0.38-0.29
Total Comprehensive Income-48.5%-76.85-51.4347267.930
Earnings Per Share, Basic-32.3%-4.41-3.093.181.980.672.53
Earnings Per Share, Diluted-32.3%-4.36-3.053.141.940.62.53
Debt equity ratio-05100000
Debt service coverage ratio-07700000
Description(%) Q/QDec-2025Sep-2025Jun-2025Mar-2025Dec-2024Sep-2024
Revenue From Operations-10.3%219244191273205227
Other Income-47%5.77103.69106.823.08
Total Income-11.5%225254195283212230
Cost of Materials-2.7%11111499150106151
Purchases of stock-in-trade69.8%0.810.370.470.580.4814
Employee Expense5.6%201919191720
Finance costs-22.2%151911171718
Depreciation and Amortization8.3%141313131313
Other expenses-7%677266747063
Total Expenses-11.7%228258212271219244
Profit Before exceptional items and Tax4.2%-3.61-3.81-16.3812-7.19-14.27
Exceptional items before tax--13.66000.260-96.27
Total profit before tax-279.8%-17.27-3.81-16.3812-7.19-110.54
Current tax-000005.44
Deferred tax-350.4%-4.27-0.17-5.7-3.72-1.57-43.36
Total tax-350.4%-4.27-0.17-5.7-3.72-1.57-37.91
Total profit (loss) for period-201.7%-13-3.64-10.6816-5.63-72.62
Other comp. income net of taxes87%0.32-4.250.221.94-2.32-0.72
Total Comprehensive Income-53.8%-12.67-7.89-10.4618-7.95-73.34
Earnings Per Share, Basic-42%-0.69-0.19-0.570.86-0.33-4.34
Earnings Per Share, Diluted-42%-0.69-0.19-0.560.85-0.327-4.29
Debt equity ratio----051--
Debt service coverage ratio----077--

Balance Sheet for Camlin Fine Sciences

Consolidated figures (in Rs. Crores) /
Description(%) Q/QSep-2025Mar-2025Sep-2024Mar-2024Sep-2023Mar-2023
Cash and cash equivalents-16.5%8710480809294
Current investments5.4%40380000
Loans, current0%10102.33101010
Total current financial assets-6.2%499532415391358418
Inventories0.8%531527501513591568
Total current assets-1.4%1,1671,1831,0199991,0471,086
Property, plant and equipment6.2%630593583757780794
Capital work-in-progress60.4%159.7322465041
Investment property0%2.162.160000
Goodwill0%474776475353
Non-current investments27.3%2923237.887.887.96
Total non-current financial assets25%463738222225
Total non-current assets3.6%870840864951965972
Total assets0.6%2,0372,0241,8851,9522,0142,060
Borrowings, non-current8.2%290268341333351408
Total non-current financial liabilities5.5%310294341350369423
Provisions, non-current25%6.65.485.595.114.774.81
Total non-current liabilities5.6%320303369362390443
Borrowings, current-6.6%352377399325315371
Total current financial liabilities1.1%826817783690628730
Provisions, current20%1311109.589.4510
Current tax liabilities-2.5%2.182.212.150.196.914
Total current liabilities1.2%856846851732681793
Total liabilities2.4%1,1771,1491,2201,0951,0711,236
Equity share capital0%191917171716
Non controlling interest-9.2%-29.45-26.89-24.47-7.8-0.764.71
Total equity-1.7%860875665857942824
Total equity and liabilities0.6%2,0372,0241,8851,9522,0142,060
Standalone figures (in Rs. Crores) /
Description(%) Q/QSep-2025Mar-2025Sep-2024Mar-2024Sep-2023Mar-2023
Cash and cash equivalents-68.6%12360.230.680.1422
Current investments5.4%40380000
Loans, current5.2%625957524330
Total current financial assets1.9%641629471582564549
Inventories-5.3%249263252255281142
Total current assets-4.2%890929748858864718
Property, plant and equipment2.7%534520516560564282
Capital work-in-progress48.1%139.1243135207
Investment property0%2.162.160000
Non-current investments4.8%676464808282
Loans, non-current-0004.69126.8
Total non-current financial assets9.1%736767889895
Total non-current assets-0.3%697699706711724625
Total assets-2.6%1,5871,6291,4561,5721,5901,346
Borrowings, non-current9.4%188172195222237258
Total non-current financial liabilities7.2%195182195237252268
Provisions, non-current25.5%6.425.325.444.974.653.32
Total non-current liabilities7.5%201187214249272282
Borrowings, current-19.3%218270313269244190
Total current financial liabilities-6.5%530567565580506442
Provisions, current26%3.963.353.133.022.481.7
Current tax liabilities---0.0106.255.62
Total current liabilities-6.7%541580613607546472
Total liabilities-3.1%742766826856818754
Equity share capital0%191917171716
Total equity-2.1%844862630716772592
Total equity and liabilities-2.6%1,5871,6291,4561,5721,5901,346

Cash Flow for Camlin Fine Sciences

Consolidated figures (in Rs. Crores) /
Description(%) Q/QMar-2025Mar-2024Mar-2023Mar-2022Mar-2021Mar-2020
Finance costs67.8%100605836--
Depreciation-6.4%74796356--
Impairment loss / reversal-14609.680--
Unrealised forex losses/gains-30.6%2637-8.88-16.96--
Adjustments for interest income-534.8%01.230.731.56--
Share-based payments-1%00.012.367.39--
Net Cashflows from Operations-65.6%6518771176--
Income taxes paid (refund)-21.3%38482030--
Net Cashflows From Operating Activities-81.2%2713951145--
Cashflows used in obtaining control of subsidiaries-00066--
Cash payment for investment in partnership firm or association of persons or LLP-31000--
Proceeds from sales of PPE-127.3%00.560.90--
Purchase of property, plant and equipment-31.7%4261144214--
Dividends received-0.82000--
Interest received-160.9%0.861.230.731.7--
Other inflows (outflows) of cash42%-4.05-7.712928--
Net Cashflows From Investing Activities-13.1%-75.35-66.5-124.63-249.13--
Proceeds from issuing shares-2230095--
Proceeds from exercise of stock options-92.9%0.190.580.550--
Proceeds from borrowings-104.2%02581106--
Repayments of borrowings-710-52.2730--
Payments of lease liabilities-10%10118.228.83--
Interest paid-4.2%70735225--
Other inflows (outflows) of cash96.6%0-28.13-13.85-0.71--
Net Cashflows from Financing Activities181.6%72-85.9760136--
Net change in cash and cash eq.258.7%24-13.49-14.0732--
Standalone figures (in Rs. Crores) /
Description(%) Q/QMar-2025Mar-2024Mar-2023Mar-2022Mar-2021Mar-2020
Finance costs22.6%66545733--
Change in inventories97.7%0-41.6700--
Depreciation8.3%53493327--
Unrealised forex losses/gains1.8%6.786.68-19.23-5.75--
Adjustments for interest income39.6%6.224.744.14.11--
Share-based payments-002.347.36--
Net Cashflows from Operations-77.8%231002648--
Income taxes paid (refund)-98.8%1.2187.391.15--
Net Cashflows From Operating Activities-74.1%22821947--
Cashflows used in obtaining control of subsidiaries-0006.55--
Cash payment for investment in partnership firm or association of persons or LLP-31000--
Proceeds from sales of PPE93.5%0.940.0800--
Purchase of property, plant and equipment-45%2341131189--
Interest received87.5%0.940.520.651.61--
Other inflows (outflows) of cash-305.9%-34.72-7.82928--
Net Cashflows From Investing Activities-68.2%-87.66-51.72-114.73-172.33--
Proceeds from issuing shares-2230095--
Proceeds from exercise of stock options-138.1%00.580.550--
Proceeds from borrowings-107.7%01412188--
Repayments of borrowings14900%611.4021--
Payments of lease liabilities-7.7303.982.25--
Interest paid15.2%54473931--
Net Cashflows from Financing Activities385.3%101-34.0578129--
Net change in cash and cash eq.828.1%35-3.67-17.823.39--

What does Camlin Fine Sciences Ltd do?

Specialty Chemicals•Chemicals•Small Cap
Industry Group:Chemicals & Petrochemicals
Employees:624
Website:www.camlinfs.com

Important Disclosure & Data Context

This is an informational page just to provide a quick 'first look' at the stock. You must do your own deeper research. Know your risk appetite. Consult a SEBI-registered financial advisor before making any investment decisions.

Performance Comparison

CAMLINFINE vs Chemicals (2021 - 2026)

CAMLINFINE is underperforming relative to the broader Chemicals sector and has declined by 48.5% compared to the previous year.